MedTrace Logo

Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)

NCT05456074 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2022-11-25

No results posted yet for this study

Summary

Microphthalmia transcription factor (MiT) family translocation renal cell carcinomas (TRCC) are rare subtypes of kidney cancers, which often arise in children and young adults. TRCC are characterized by translocations affecting transcription factors: Transcription Factor Binding To Immunoglobulin Heavy Constant Mu Enhancer 3 (TFE3) and Transcription Factor EB (TFEB). Little is known about TRCC molecular heterogeneity, in particular their transcriptomic and epigenetic subtype classification. Clinical behavior of TRCC is varying with age and Tumor, Node, Metastasis (TNM) stage. However, the biological basis of this aggressiveness is poorly understood.

PURPOSE: The primary goal of this study is to decipher specific alterations in aggressive TRCC, defined as cases with metastatic dissemination at diagnosis. To tackle this problem, a retrospective cohort of TRCC cases in children and young adults will be created. We will then perform integrative comprehensive multi-omics analysis of these tumors to identify genetic, epigenetic and immune biomarkers associated with metastatic behavior in a training and validation datasets. Comparison of the multi-omics data will be compared to other type of rare Kidney tumors as well as clear-cell renal cell carcinomas

Conditions

  • Renal Carcinoma

Interventions

OTHER

Data collection

Retrospective data collection

Sponsors & Collaborators

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • Ministry of Health, France

    collaborator OTHER_GOV

  • Institut de cancérologie Strasbourg Europe

    lead OTHER

Principal Investigators

  • Gabriel MALOUF, MD, PhD · Institut de cancérologie Strasbourg Europe

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-25
Primary Completion
2026-01-25
Completion
2026-01-25

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05456074 on ClinicalTrials.gov